Efficacy of Bortezomib-Based Regimens for Patients with Newly Diagnosed AL Amyloidosis Not Receiving ASCT Compared with Alkylators and Dexamethasone-Based Regimens

被引：0
|
作者：
Lim, Sung Won
Park, Song Ee
Cho, Jangho
Kim, Youjin
Lee, Hansang
Hong, Juhyun
Jeon, Eunseok
Choi, Jinoh
Lee, Gayeon
Kim, Byungjun
Min, Ju Hong
Kim, Jung Sun
Lee, Jung Eun
Choi, Joon Young
Park, Silvia
Kim, Seok Jin
Jang, Jun Ho
Kim, Won Seog
Jung, Chul Won
Kim, Kihyun
机构：
来源：
BLOOD | 2017年 / 130卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3114
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Phase 3b UPFRONT Study: Safety and Efficacy of Weekly Bortezomib Maintenance Therapy After Bortezomib-Based Induction Regimens In Elderly, Newly Diagnosed Multiple Myeloma Patients
    Niesvizky, Ruben
    Flinn, Ian W.
    Rifkin, Robert M.
    Gabrail, Nashat Y.
    Charu, Veena
    Clowney, Billy
    Essell, James
    Gaffar, Yousuf A.
    Warr, Thomas A.
    Neuwirth, Rachel
    Corzo, Deyanira
    Reeves, James A.
    BLOOD, 2010, 116 (21) : 272 - 272
  • [22] Prognostic impact of cytogenetic abnormalities by FISH in systemic AL amyloidosis in the era of daratumumab and bortezomib-based frontline combination regimens
    Chakraborty, Rajshekhar
    Zanwar, Saurabh
    Bhutani, Divaya
    Gertz, Morie
    Dispenzieri, Angela
    Kumar, Shaji
    D'Souza, Anita
    Patwari, Anannya
    Cowan, Andrew
    Chen, GuiZhen
    Hegenbart, Ute
    Schoenland, Stefan
    Milani, Paolo
    Palladini, Giovanni
    Sanchorawala, Vaishali
    Bodanapu, Geethika
    Lentzsch, Suzanne
    Muchtar, Eli
    AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2024, 31 : S10 - S10
  • [23] THE CHOICE OF REGIMENS BASED OF BORTEZOMIB FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: EXPERIENCES FROM CHINA
    Cai, Z.
    He, J.
    Yang, L.
    Han, X.
    Zheng, G.
    Zheng, W.
    Wei, G.
    Wu, W.
    Ye, X.
    Shi, J.
    Xie, W.
    Li, L.
    Zhang, J.
    Huang, W.
    Huang, H.
    Zhang, X.
    Fu, J.
    HAEMATOLOGICA, 2013, 98 : 607 - 607
  • [24] Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
    Krejci, Marta
    Gregora, Evzen
    Straub, Jan
    Minarik, Jiri
    Scudla, Vlastimil
    Adam, Zdenek
    Krivanova, Andrea
    Pour, Ludek
    Zahradova, Lenka
    Buchler, Tomas
    Mayer, Jiri
    Hajek, Roman
    ANNALS OF HEMATOLOGY, 2011, 90 (12) : 1441 - 1447
  • [25] Chromosome 1q21 gain is an adverse prognostic factor for newly diagnosed multiple myeloma patients treated with bortezomib-based regimens
    Liu, Xiao
    Jia, Shuangshuang
    Chu, Yuping
    Tian, Biao
    Gao, Yaya
    Zhang, Chunyan
    Zheng, Yanhua
    Jia, Weijing
    Liu, Xiangxiang
    Yuan, Ruifeng
    Zhang, Na
    Feng, Juan
    Dong, Hongjuan
    Xin, Xiaoli
    Cao, Zhengcong
    Tang, Hailong
    Chang, Ziwei
    Gao, Guangxun
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity
    Shah, Gunjan L.
    Kaul, Esha
    Fallo, Shelly
    Cossor, Furha I.
    Smith, Hedy
    Klein, Andreas K.
    Miller, Kenneth B.
    Comenzo, Raymond L.
    BLOOD, 2012, 120 (21)
  • [27] Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma
    Marta Krejci
    Evzen Gregora
    Jan Straub
    Jiri Minarik
    Vlastimil Scudla
    Zdenek Adam
    Andrea Krivanova
    Ludek Pour
    Lenka Zahradova
    Tomas Buchler
    Jiri Mayer
    Roman Hajek
    Annals of Hematology, 2011, 90 : 1441 - 1447
  • [28] Real-life experience with bortezomib-based regimens in elderly patients with newly diagnosed multiple myeloma and comorbidities: a Polish retrospective multicenter study
    Hus, Iwona
    Walter-Croneck, Adam
    Masternak, Anna
    Jurczyszyn, Artur
    Usnarska-Zubkiewicz, Lidia
    Bolkun, Lukasz
    Druzd-Sitek, Agnieszka
    Rymko, Marcin
    Letowska, Jadwiga
    Lech-Maranda, Ewa
    Pasiarski, Marcin
    Dmoszynska, Anna
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2017, 127 (11): : 765 - 774
  • [29] CTLA-4 polymorphisms are associated with treatment outcomes of patients with multiple myeloma receiving bortezomib-based regimens
    Qin, Xiao-Ying
    Lu, Jin
    Li, Guo-Xuan
    Wen, Lei
    Liu, Yang
    Xu, Lan-Ping
    Chang, Ying-Jun
    Liu, Kai-Yan
    Jiang, Zheng-Fan
    Huang, Xiao-Jun
    ANNALS OF HEMATOLOGY, 2018, 97 (03) : 485 - 495
  • [30] BORTEZOMIB-BASED REGIMENS AS FIRST-LINE OR SALVAGE THERAPY FOR POEMS PATIENTS
    Riva, M.
    Lessi, F.
    Berno, T.
    Visentin, A.
    Campagnolo, M.
    Briani, C.
    Adami, F.
    HAEMATOLOGICA, 2017, 102 : 135 - 136
12345